JNJ-63733657
Phase 2Small molecule
Johnson & JohnsonJNJ-63733657 is one of 12 small molecule programs targeting Early Alzheimer's Disease. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Early Alzheimer's Disease
#DrugCompanyPhaseTrials
1Kisunla
Eli LillyPhase 3
Tasigna
AAzurity Pharmaceuticals
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Leqembi
EisaiPhase 2
Admsc
UUniversity Hospital, Toulouse
Phase 2
E2814
EisaiPhase 2
GSK4527226
GSKPhase 2
Fasudil
WWoolsey Pharmaceuticals
Phase 2
JNJ-63733657
Johnson & JohnsonPhase 2
AD04
AADvantage Therapeutics
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JNJ-63733657. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company